Aptevo Secures $1.5M Non-Dilutive Grant for APVO451 Solid Tumor Immunotherapy
APVO sits 17% above its 52-week low of $3.8 on elevated volume (3.5× avg).
Summary
Aptevo Therapeutics secured a $1.5 million non-dilutive grant from the Andy Hill CARE Fund to advance its APVO451 trispecific immunotherapy for solid tumors, providing critical funding for a strategic preclinical program.
Key Events · Product Development and Regulatory · APVO
-
Non-Dilutive Grant Awarded
Aptevo received a $1.5 million grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support Investigational New Drug (IND)-enabling studies for APVO451, its trispecific antibody candidate for solid tumors.
-
Funding for Strategic Pipeline
The grant provides critical non-dilutive capital for APVO451, a key preclinical program advancing towards development candidate selection by year-end 2026 and initiation of IND-enabling studies in Q1 2027.
-
External Validation
The competitive award, reviewed by subject matter experts, provides external validation of APVO451's tumor-directed trispecific design and supports the company's nectin-4-targeted therapies.
Analysis · APVO · Life Sciences
This grant provides crucial non-dilutive funding for Aptevo's APVO451 program, a strategic trispecific antibody candidate for solid tumors. For a company that recently reiterated a going concern warning, securing external, non-dilutive capital to advance a key preclinical asset is highly significant, extending the development runway for this program without further shareholder dilution.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APVO was trading at $4.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $3.80 to $59.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.